Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation.
Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation.
复制标题
DOI：
10.1016/j.ijid.2020.10.093
复制
发表时间：
2021-01
期刊：
影响因子：
--
通讯作者：
Asakura H
中科院分区：
文献类型：
--
作者：
Takahashi W;Yoneda T;Koba H;Ueda T;Tsuji N;Ogawa H;Asakura H
Nafamostat是一种丝氨酸蛋白酶抑制剂，具有抗凝血酶、抗纤溶酶和抗胰蛋白酶等多种作用，已被用于临床治疗弥散性血管内凝血（DIC）和胰腺炎。本病例报告描述了1例COVID-19肺炎患者的临床过程，该患者可能由DIC和肺栓塞引起的严重低氧血症，经肝素和那莫他他联合治疗显着改善。此外，本文还讨论了那莫他抗COVID-19的有益机制以及关注高钾血症的必要性。
Nafamostat, a serine proteinase inhibitor with various actions including antithrombin, antiplasmin, and antitrypsin effects, has been used in clinical practice to treat disseminated intravascular coagulation (DIC) and pancreatitis. This case report describes the clinical course of a patient with COVID-19 pneumonia whose severe hypoxemia, probably caused by DIC and pulmonary embolism, showed remarkable improvement with combination heparin and nafamostat therapy. In addition, beneficial mechanisms of nafamostat against COVID-19 and the necessity of attention to hyperkalemia as an adverse effect are discussed.
登录
查看更多内容
影响因子：
7.1
作者：
Asakura H
通讯作者：
Asakura H
DOI：
10.1254/jjp.35.203
发表时间：
1984-01-01
期刊：
JAPANESE JOURNAL OF PHARMACOLOGY
影响因子：
--
作者：
AOYAMA, T;INO, Y;FUJITA, M
通讯作者：
FUJITA, M
影响因子：
10.4
作者：
Tang, Ning;Li, Dengju;Sun, Ziyong
通讯作者：
Sun, Ziyong
影响因子：
4.9
作者：
Yamamoto, Mizuki;Matsuyama, Shutoku;Matsuda, Zene
通讯作者：
Matsuda, Zene
影响因子：
64.5
作者：
Hoffmann, Markus;Kleine-Weber, Hannah;Poehlmann, Stefan
通讯作者：
Poehlmann, Stefan